- ►nih.gov [PDF] JB Hibbs Jr, C Westenfelder, R Taintor, Z … - Journal of Clinical …, 1992 - pubmedcentral.nih.gov Aninterferon-'y,tumornecrosis factor, and interleukin-1-induc- ible, high-output pathway
synthesizing nitric oxide (NO) from L-arginine was recently identified in rodents. High-dose inter-
leukin-2 (IL-2) therapy is known to ... Cited by 334 - Related articles - All 6 versions
- ►ascopubs.org [PDF] KA Margolin, AA Rayner, MJ Hawkins, MB … - Journal of Clinical …, 1989 - jco.ascopubs.org From the City of Hope Cancer Research Center, Duarte, CA; University of California at San Francisco;
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Tufts-New England
Medical Center, Boston; Albert ... Cited by 225 - Related articles - All 6 versions
- ►pnas.org [PDF] W Schmidt, T Schweighoffer, E Herbst, G … - Proceedings of the …, 1995 - National Acad Sciences Page 1. Proc. Natl. Acad. Sci. USA Vol. 92, pp. 4711-4714, May 1995 Medical Sciences Cancer vaccines:
The interleukin 2 dosage effect (granulocyte-macrophage colony-stimulating factor/tumor vaccine/murine
melanoma) WALTER SCHMIDT*, TAMAS SCHWEIGHOFFER*, ELKE HERBST*, GERHARD MAASS*, MANFRED BERGER*, ... Cited by 112 - Related articles - BL Direct - All 8 versions
SS Legha, S Ring, N Papadopoulos, C Plager … - CA A Cancer Journal … - interscience.wiley.com Based on the independent activity of cisplatin, vinblastine, and
dimethyl-triazeno-imidazole-carboxamide (DTIC) (CVD), a combination of these agents was used in the
treatment of patients with advanced ... Cited by 106 - Related articles - All 4 versions
- ►ascopubs.org [PDF] J Atzpodien, E Lopez Hanninen, H Kirchner, … - Journal of Clinical …, 1995 - jco.ascopubs.org Purpose: In a phase II multiinstitutional outpatient trial, patients with progressive metastatic
renal cell carci- noma were treated with a combination of subcutaneous (SC) recombinant
interleukin-2 (rlL-2) and ... Cited by 106 - Related articles - BL Direct - All 6 versions
- ►bloodjournal.org L Bowman, M Grossmann, D Rill, M Brown, W Zhong, B … - Blood, 1998 - Am Soc Hematology In many different murine models, the immunogenicity of tumor cells can be increased by transduction
with a range of immunostimulatory genes, inducing an immune response that causes regression of
pre-existing unmodified tumor ... Cited by 98 - Related articles - BL Direct - All 4 versions
RO Dillman, C Church, RK Oldham, WH West, … - CA A Cancer Journal … - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets. In
this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the ... Cited by 91 - Related articles - BL Direct - All 3 versions
- ►pnas.org [PDF] G Maass, W Schmidt, M Berger, F … - Proceedings of the …, 1995 - National Acad Sciences Page 1. Proc. Natl. Acad. Sci. USA Vol. 92, pp. 5540-5544, June 1995 Medical Sciences Priming of
tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor
cells: Three consecutive stages may be required for successful tumor vaccination ... Cited by 75 - Related articles - BL Direct - All 9 versions
CE Hack, AC Ogilvie, B Eisele, AJM Eerenberg, J … - Intensive Care Medicine, 1993 - Springer Abstract. C l-inhibitor (C I-INH) is the major plasma in- hibitor of the complement and contact
systems. Activa- tion of either system has been shown to occur in patients with septic shock and is
associated with a poor outcome. ... Cited by 71 - Related articles - BL Direct - All 4 versions
ME Brewster, MS Hora, JW Simpkins, N Bodor - Pharmaceutical research, 1991 - Springer 794 Brewster, Hora, Simpkins, and Bodor Table II. Effect of Various Storage Conditions on the
Clarity of IL-2 Formulations" Fig. 2. Effect of various concentrations of 2-hydroxypropyl-ß-
cyclodextrin on solution clarity of ... Cited by 69 - Related articles - All 4 versions
